Fate Therapeutics Statistics
Total Valuation
FATE has a market cap or net worth of $281.58 million. The enterprise value is $203.48 million.
| Market Cap | 281.58M |
| Enterprise Value | 203.48M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FATE has 119.82 million shares outstanding. The number of shares has increased by 1.19% in one year.
| Current Share Class | 119.82M |
| Shares Outstanding | 119.82M |
| Shares Change (YoY) | +1.19% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 1.44% |
| Owned by Institutions (%) | 57.97% |
| Float | 105.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.38 |
| Forward PS | 59.59 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.49.
| Current Ratio | 4.85 |
| Quick Ratio | 4.75 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.75% and return on invested capital (ROIC) is -28.96%.
| Return on Equity (ROE) | -60.75% |
| Return on Assets (ROA) | -26.22% |
| Return on Invested Capital (ROIC) | -28.96% |
| Return on Capital Employed (ROCE) | -58.23% |
| Weighted Average Cost of Capital (WACC) | 14.39% |
| Revenue Per Employee | $40,317 |
| Profits Per Employee | -$782,584 |
| Employee Count | 161 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.67% in the last 52 weeks. The beta is 2.55, so FATE's price volatility has been higher than the market average.
| Beta (5Y) | 2.55 |
| 52-Week Price Change | +132.67% |
| 50-Day Moving Average | 2.51 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 43.31 |
| Average Volume (20 Days) | 1,458,024 |
Short Selling Information
The latest short interest is 9.39 million, so 7.83% of the outstanding shares have been sold short.
| Short Interest | 9.39M |
| Short Previous Month | 9.11M |
| Short % of Shares Out | 7.83% |
| Short % of Float | 8.92% |
| Short Ratio (days to cover) | 7.80 |
Income Statement
In the last 12 months, FATE had revenue of $6.49 million and -$126.00 million in losses. Loss per share was -$1.05.
| Revenue | 6.49M |
| Gross Profit | -77.93M |
| Operating Income | -132.49M |
| Pretax Income | -126.00M |
| Net Income | -126.00M |
| EBITDA | -120.50M |
| EBIT | -132.49M |
| Loss Per Share | -$1.05 |
Balance Sheet
The company has $153.77 million in cash and $75.68 million in debt, with a net cash position of $78.10 million or $0.65 per share.
| Cash & Cash Equivalents | 153.77M |
| Total Debt | 75.68M |
| Net Cash | 78.10M |
| Net Cash Per Share | $0.65 |
| Equity (Book Value) | 153.44M |
| Book Value Per Share | 1.31 |
| Working Capital | 125.36M |
Cash Flow
In the last 12 months, operating cash flow was -$101.94 million and capital expenditures -$3.71 million, giving a free cash flow of -$105.66 million.
| Operating Cash Flow | -101.94M |
| Capital Expenditures | -3.71M |
| Depreciation & Amortization | 11.99M |
| Net Borrowing | n/a |
| Free Cash Flow | -105.66M |
| FCF Per Share | -$0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,041.13% |
| Pretax Margin | -1,941.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FATE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.19% |
| Shareholder Yield | -1.19% |
| Earnings Yield | -44.75% |
| FCF Yield | -37.52% |
Analyst Forecast
The average price target for FATE is $5.74, which is 144.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.74 |
| Price Target Difference | 144.26% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | -15.51% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FATE has an Altman Z-Score of -8.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.8 |
| Piotroski F-Score | 2 |